The report analyzes and forecasts the hereditary angioedema market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of hereditary angioedema, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major hereditary angioedema companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of hereditary angioedema upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of hereditary angioedema and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global hereditary angioedema market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the hereditary angioedema market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of hereditary angioedema market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
The report also profiles major players in the hereditary angioedema market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Shire plc, CSL Limited, Pharming Group NV, Ionis Pharmaceuticals, Inc. and iBio, Inc.
The global hereditary angioedema market has been segmented as below:
Global Hereditary Angioedema Market, by Drug Class
Global Hereditary Angioedema Market, by Route of Administration
Global Hereditary angioedema Market, by Distribution Channel
Global Hereditary Angioedema Market, by Geography
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Hereditary Angioedema Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Market Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.3.4. Trends
4.4. Hereditary Angioedema Market Analysis and Forecast, 2017 – 2025
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Market Outlook
4.6. Porter’s five forces analysis
4.7. Value Chain Analysis
4.8. Pipeline Analysis
4.9. Orphan Drug Exclusivity Details
4.10. Disease Overview
5. Global Hereditary Angioedema Market Analysis and Forecasts, By Drug Class
5.1. Introduction & Definition
5.2. Key Findings
5.3. Key Trends
5.4. Market Size (US$ Mn) Forecast By Drug Class
5.4.1. C1 esterase inhibitor
5.4.1.1. Cinryze
5.4.1.2. Berinert
5.4.1.3. Ruconest
5.4.2. Selective bradykinin B2 receptor antagonist
5.4.2.1. Firazyr
5.4.3. Kallikrein inhibitor
5.4.3.1. Kalbitor
5.4.4. Others
5.4.4.1. Conventional Drugs
5.4.4.2. Pipeline Drugs
5.5. Comparison Matrix
5.6. Market Attractiveness By Drug Class
6. Global Hereditary Angioedema Market Analysis and Forecasts, By Route of Administration
6.1. Introduction & Definition
6.2. Key Findings
6.3. Market Size (US$ Mn) Forecast By Route of Administration
6.3.1. Intravenous
6.3.2. Subcutaneous injection
6.3.3. Oral
6.4. Comparison Matrix
6.5. Market Attractiveness By Route of Administration
7. Global Hereditary Angioedema Market Analysis and Forecasts, By Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings
7.3. Key Trends
7.4. Market Size (US$ Mn) Forecast By Distribution Channel
7.4.1. Hospital pharmacies
7.4.2. Retail pharmacies
7.4.3. Others
7.5. Comparison Matrix
7.6. Market Attractiveness By Distribution Channel
8. Global Hereditary Angioedema Market Analysis and Forecasts, By Region
8.1. Key Findings
8.2. Key Trends
8.3. Market Size (US$ Mn) Forecast By Region
8.3.1. North America
8.3.2. Europe
8.3.3. Rest of the World
8.4. Market Attractiveness By Region
9. North America Hereditary Angioedema Market Analysis and Forecast
9.1. Key Findings
9.2. Policies and Regulations
9.3. Market Overview
9.4. Market Size (US$ Mn) Forecast By Drug Class
9.4.1. C1 esterase inhibitor
9.4.1.1. Cinryze
9.4.1.2. Berinert
9.4.1.3. Ruconest
9.4.2. Selective bradykinin B2 receptor antagonist
9.4.2.1. Firazyr
9.4.3. Kallikrein inhibitor
9.4.3.1. Kalbitor
9.4.4. Others
9.4.4.1. Conventional Drugs
9.4.4.2. Pipeline Drugs
9.5. Market Size (US$ Mn) Forecast By Route of Administration
9.5.1. Intravenous
9.5.2. Subcutaneous injection
9.5.3. Oral
9.6. Market Size (US$ Mn) Forecast By Distribution Channel
9.6.1. Hospital pharmacies
9.6.2. Retail pharmacies
9.6.3. Others
9.7. Market Size by Value (US$ Mn) Forecast, By Country
9.7.1. U.S.
9.7.2. Canada
9.8. Market Attractiveness Analysis
9.8.1. By Drug Class
9.8.2. By Route of Administration
9.8.3. By Distribution Channel
9.8.4. By Country
10. Europe Hereditary Angioedema Market Analysis and Forecast
10.1. Key Findings
10.2. Policies and Regulations
10.3. Market Overview
10.4. Market Size (US$ Mn) Forecast By Drug Class
10.4.1. C1 esterase inhibitor
10.4.1.1. Cinryze
10.4.1.2. Berinert
10.4.1.3. Ruconest
10.4.2. Selective bradykinin B2 receptor antagonist
10.4.2.1. Firazyr
10.4.3. Others
10.4.3.1. Conventional Drugs
10.4.3.2. Pipeline Drugs
10.5. Market Size (US$ Mn) Forecast By Route of Administration
10.5.1. Intravenous
10.5.2. Subcutaneous injection
10.5.3. Oral
10.6. Market Size (US$ Mn) Forecast By Distribution Channel
10.6.1. Hospital pharmacies
10.6.2. Retail pharmacies
10.6.3. Others
10.7. Market Size by Value (US$ Mn) Forecast, By Country
10.7.1. Germany
10.7.2. U.K.
10.7.3. France
10.7.4. Spain
10.7.5. Italy
10.7.6. Rest of Europe
10.8. Market Attractiveness Analysis
10.8.1. By Drug Class
10.8.2. By Route of Administration
10.8.3. By Distribution Channel
10.8.4. By Country / Sub-region
11. Rest of The World Hereditary Angioedema Market Analysis and Forecast
11.1. Key Findings
11.2. Policies and Regulations
11.3. Market Overview
11.4. Market Size (US$ Mn) Forecast By Drug Class
11.4.1. C1 esterase inhibitor
11.4.1.1. Cinryze
11.4.1.2. Berinert
11.4.1.3. Ruconest
11.4.2. Selective bradykinin B2 receptor antagonist
11.4.2.1. Firazyr
11.4.3. Kallikrein inhibitor
11.4.3.1. Kalbitor
11.4.4. Others
11.4.4.1. Conventional Drugs
11.4.4.2. Pipeline Drugs
11.5. Market Size (US$ Mn) Forecast By Route of Administration
11.5.1. Intravenous
11.5.2. Subcutaneous injection
11.5.3. Oral
11.6. Market Size (US$ Mn) Forecast By Distribution Channel
11.6.1. Hospital pharmacies
11.6.2. Retail pharmacies
11.6.3. Others
11.7. Market Attractiveness Analysis
11.7.1. By Drug Class
11.7.2. By Route of Administration
11.7.3. By Distribution Channel
12. Competition Landscape
12.1. Market Share Analysis
12.2. Market Player – Competition Matrix (By Tier and Size of companies)
12.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
12.3.1. Shire plc
12.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
12.3.1.2. Product Portfolio
12.3.1.3. SWOT Analysis
12.3.1.4. Financial Overview
12.3.1.5. Strategic Overview
12.3.2. CSL Limited
12.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
12.3.2.2. Product Portfolio
12.3.2.3. SWOT Analysis
12.3.2.4. Financial Overview
12.3.2.5. Strategic Overview
12.3.3. Pharming Group NV
12.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
12.3.3.2. Product Portfolio
12.3.3.3. SWOT Analysis
12.3.3.4. Financial Overview
12.3.3.5. Strategic Overview
12.3.4. Ionis Pharmaceuticals, Inc.
12.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
12.3.4.2. Product Portfolio
12.3.4.3. SWOT Analysis
12.3.4.4. Financial Overview
12.3.4.5. Strategic Overview
12.3.5. iBio Inc.
12.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
12.3.5.2. Product Portfolio
12.3.5.3. SWOT Analysis
12.3.5.4. Financial Overview
12.3.5.5. Strategic Overview
12.2.6. BioCryst Pharmaceuticals, Inc.
12.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
12.3.6.2. Product Portfolio
12.3.6.3. SWOT Analysis
12.3.6.4. Financial Overview
12.3.6.5. Strategic Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers